PsychoGenics Inc.
PsychoGenics is a preclinical CRO specializing in CNS and orphan disorders, providing validated disease models and comprehensive preclinical capabilities to support drug discovery and development. Their mission is to help companies discover breakthroughs for severely disabling CNS and orphan disorders, reducing attrition in clinical development through high-quality, translational research and customized solutions.
Industries
Nr. of Employees
medium (51-250)
PsychoGenics Inc.
Patents
Products
IND-ready ENT1 inhibitor candidate (licensed development program)
An investigational ENT1 transporter inhibitor candidate acquired under license for development as a potential treatment for sleep and seizure disorders and other CNS indications.
IND-ready ENT1 inhibitor candidate (licensed development program)
An investigational ENT1 transporter inhibitor candidate acquired under license for development as a potential treatment for sleep and seizure disorders and other CNS indications.
Services
Design and execution of automated and standard rodent behavioral assays for screening, characterization and lead optimization.
Collection and ML-based analysis of EEG to generate translational biomarkers and predict therapeutic applications of CNS-active compounds.
Neurophysiological recordings and microdialysis sampling to assess neuronal activity and neurochemical responses to interventions.
Ex vivo biomarker quantification, tissue histology and quantitative immunohistochemistry for target engagement and pathology assessment.
Preclinical pharmacokinetic and pharmacodynamic study design and bioanalysis to define exposure–response relationships.
Preclinical assessment of target occupancy to support mechanism-of-action characterization.
Design and execution of automated and standard rodent behavioral assays for screening, characterization and lead optimization.
Collection and ML-based analysis of EEG to generate translational biomarkers and predict therapeutic applications of CNS-active compounds.
Neurophysiological recordings and microdialysis sampling to assess neuronal activity and neurochemical responses to interventions.
Ex vivo biomarker quantification, tissue histology and quantitative immunohistochemistry for target engagement and pathology assessment.
Preclinical pharmacokinetic and pharmacodynamic study design and bioanalysis to define exposure–response relationships.
Preclinical assessment of target occupancy to support mechanism-of-action characterization.
Expertise Areas
- Phenotypic in vivo drug discovery
- Preclinical CNS pharmacology
- AI / machine-learning for pharmacology
- Translational EEG and electrophysiology
Key Technologies
- AI-driven phenotypic screening
- Computer vision for behavioral analysis
- Machine-learning classifiers trained on reference compound libraries
- Pharmaco-EEG and EEG spectral analysis
News & Updates
PsychoGenics received a contract from NIH to evaluate novel therapeutics for pain, funded by the NIH HEAL Initiative, with a maximum value of $80 million over 5 years.
PsychoGenics announced the launch of eCube, an AI-enabled pharmaco-EEG platform to support phenotypic drug discovery for neuropsychiatric disorders.
PsychoGenics received a $3 million SBIR grant from NIMH to use its AI-enabled EEG platform, eCube, to identify new applications for existing drugs targeting rare diseases.
PsychoGenics was recognized as a top marketplace supplier for 2023 by scientist.com.
PsychoGenics announced the appointment of Dr. Daniela Brunner as Chief Innovation Officer, Dr. Geoffrey Varty as EVP of Research Operations, and Dr. Leslie Street as VP of Medicinal Chemistry.
PsychoGenics was recognized as a top marketplace supplier for 2023 by scientist.com.
PsychoGenics received a contract from NIH to evaluate novel therapeutics for pain, funded by the NIH HEAL Initiative, with a maximum value of $80 million over 5 years.
PsychoGenics announced the launch of eCube, an AI-enabled pharmaco-EEG platform to support phenotypic drug discovery for neuropsychiatric disorders.
PsychoGenics received a $3 million SBIR grant from NIMH to use its AI-enabled EEG platform, eCube, to identify new applications for existing drugs targeting rare diseases.
PsychoGenics was recognized as a top marketplace supplier for 2023 by scientist.com.
PsychoGenics announced the appointment of Dr. Daniela Brunner as Chief Innovation Officer, Dr. Geoffrey Varty as EVP of Research Operations, and Dr. Leslie Street as VP of Medicinal Chemistry.
PsychoGenics was recognized as a top marketplace supplier for 2023 by scientist.com.